Connect with us

Hi, what are you looking for?

press release

Europe approves Roche’s first bispecific antibody for Two Eye – Press Release

aapharma 5

  • That European Commission approved Roche Holding Ltd RHHBY Vabysmo (faricimab) for neovascular or “wet” age-related macular degeneration (nAMD) and visual impairment due to diabetic macular edema (DME).
  • These retinal diseases affect more than 40 million people worldwide.
  • Vabysmo is the only injectable eye medicine approved in Europe with Phase 3 studies supporting treatment up to four months apart for people with nAMD and DME.
  • also read: WHO recommends against Roche to deprecate GSK’s COVID-19 therapies
  • The approval is based on four phase 3 studies with 3,220 patients. The studies showed that patients treated with Vabysmo up to every four months had similar results to those treated with aflibercept every two months.
  • The pooled data from all four studies after two years showed that more than 60% of people treated with Vabysmo were able to extend treatment to every four months while improving and maintaining vision.
  • In addition, patients with nAMD and DME treated with Vabysmo received a median of 33% (10 vs. 15) and 21% (11 vs. 14), respectively, fewer injections than aflibercept for up to two years.
  • Vabysmo is now approved in the European Union and nine other countries. More than 100,000 Vabysmo doses have been distributed worldwide.
  • Price promotion: RHHBY shares traded 1.70% lower at $41.63 on the latest check Monday.

Source Story here

You May Also Like

Business

State would join dozens of others in enacting legislation based on federal government’s landmark whistleblower statute, the False Claims Act

press release

With a deep understanding of the latest tech, Erbo helps businesses flourish in a digital world.

press release

#Automotive #Carbon #Canister #Market #Projected #Hit #USD New York, US, Oct. 24, 2022 (GLOBE NEWSWIRE) —  According to a comprehensive research report by Market...

press release

Barrington Research Analyst James C.Goss reiterated an Outperform rating on shares of IMAX Corp IMAX with a Price target of $20. As theaters...